3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
15
Neoplasms
4
Neoplasm Metastasis
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Tuberous Sclerosis
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Obesity
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Lymphoma
1
Lung Neoplasms
1
Lung Diseases
1
Kidney Neoplasms
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms, Male
1
Acrocephalosyndactylia
1
Interventions
osimertinib
2
Pemetrexed
2
Carboplatin
2
exemestane
1
entinostat
1
Tyrosine Kinase Inhibitors
1
Erlotinib Hydrochloride
1
Dasatinib
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Respiratory Tract Diseases
×
exemestane
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled